Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Autor:
Kristan H. Cleveland, Abdullah Shamim, Sherry Liang, Ying Huang, Mengbing Chen, Cyrus Parsa, Bradley T. Andresen, Ayaz Shahid, Robert Orlando
Publikováno v:
Cancer Prev Res (Phila)
Skin cancer is the most common malignancy worldwide and is rapidly rising in incidence, representing a significant public health challenge. The β-blocker, carvedilol, has shown promising effects in preventing skin cancer. However, as a potent β-blo
Autor:
Aaron Smith, Peter Johnström, Katarina Varnäs, James Atkinson, Minghui Zhao, Nicole Strittmatter, Yumei Yan, Ryosuke Arakawa, Nicola Colclough, Annika Janefeldt, M. Raymond V. Finlay, Albert D. Windhorst, Evgeny Revunov, Natasha A. Karp, Kan Chen, Lin Zhang, Gareth Maglennon, Peter Barton, Richard J. A. Goodwin, Ana Vazquez-Romero, Magnus Schou, Akihiro Takano, Gail L. Wrigley, Darren Cross, Mikhail Kondrashov, Mohammad Mahdi Moein, Zack Cheng, Paul D. Smith, Sally J. Adua, Richard A. Ward, Lars Farde, James W.T. Yates, Joanne Wilson, Jonas Malmquist, Don X. Nguyen
Publikováno v:
Colclough, N, Chen, K, Johnstrom, P, Strittmatter, N, Yan, Y, Wrigley, G L, Schou, M, Goodwin, R, Varnas, K, Adua, S J, Zhao, M, Nguyen, D X, Maglennon, G, Barton, P, Atkinson, J, Zhang, L, Janefeldt, A, Wilson, J, Smith, A, Takano, A, Arakawa, R, Kondrashov, M, Malmquist, J, Revunov, E, Vazquez-Romero, A, Moein, M M, Windhorst, A D, Karp, N A, Finlay, R V, Ward, R A, Yates, J W T, Smith, P D, Farde, L, Cheng, Z & Cross, D A E 2021, ' Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs ', Clinical Cancer Research, vol. 27, no. 1, pp. 189-201 . https://doi.org/10.1158/1078-0432.CCR-19-1871
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–brain barrier (BBB) permeability is considered desirable for incre
Autor:
Stepan Chuprakov, Fangjiu Zhang, Yun Cheol Kim, David Rabuka, Dominick Yeo, Robyn M. Barfield, Penelope M. Drake, Ayodele O. Ogunkoya, Mark D. Pegram, Maxine Bauzon, Colin Hickle
Publikováno v:
Molecular Cancer Therapeutics. 19:1866-1874
Trastuzumab and the related antibody-drug conjugate (ADC), ado-trastuzumab emtansine (T-DM1), both target HER2-overexpressing cells. Together, these drugs have treatment indications in both early-stage and metastatic settings for HER2+ breast cancer.
Autor:
David L. Kerr, Jason A. Somarelli, William C. Eward, Gireesh B. Reddy, David S. Hsu, David Needham, Brian E. Brigman, Artak Tovmasyan, Ivan Spasojevic
Publikováno v:
Molecular Cancer Therapeutics. 19:1448-1461
Therapeutic advances for osteosarcoma have stagnated over the past several decades, leading to an unmet clinical need for patients. The purpose of this study was to develop a novel therapy for osteosarcoma by reformulating and validating niclosamide,
Autor:
Zhiduan Cai, Yu Zheng, Yong Luo, Yuxiang Liang, Yangjia Zhuo, Ren Liu, Yulin Deng, Xuejin Zhu, Yingke Liang, Jianheng Ye, Jianjiang Xie, Ru-Jun Mo, Zhao-Dong Han, Weide Zhong, Yuanfa Feng, Yong-ding Wu, Chin-Lee Wu, Jianguo Zhu, Funeng Jiang
Publikováno v:
Cancer Research. 80:2150-2162
Metformin is an oral drug widely used for the treatment of type 2 diabetes mellitus. Numerous studies have demonstrated the value of metformin in cancer treatment. However, for metformin to elicit effects on cancer often requires a high dosage, and a
Autor:
Terje Sundstrøm, Christopher Florian Holte, Olav Tenstad, Zaynah Maherally, Geoffrey J. Pilkington, Tuyen Hoang, Tine Veronika Karlsen, Habib Baghirov, Rolf Bjerkvig, Frits Thorsen, Anne Vaag Eikeland, Gobinda Sarkar, Hrvoje Miletic, Olivier Keunen, Robert B. Jenkins, Synnøve Nymark Aasen, Dag Erlend Olberg, Heidi Espedal
Publikováno v:
Aasen, S N, Espedal, H, Holte, C F, Keunen, O, Karlsen, T V, Tenstad, O, Maherally, Z, Miletic, H, Hoang, T, Eikeland, A V, Baghirov, H, Olberg, D E, Pilkington, G J, Sarkar, G, Jenkins, R B, Sundstrøm, T, Bjerkvig, R & Thorsen, F 2019, ' Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood–brain barrier ', Molecular Cancer Therapeutics, vol. 18, no. 11, pp. 2171-2181 . https://doi.org/10.1158/1535-7163.MCT-19-0160
Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood–brain barrier (BBB) is likely intact, which inhibits sufficient drug deliv
Publikováno v:
Mol Cancer Ther
Somatostatin analogues have been examined as a treatment for somatostatin receptor overexpressing tumors for years; specifically, octreotate (TATE) and octreotide (TOC). Several versions of these analogues coupled to beta or gamma nuclides are curren
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
Tatsushi Yokogawa, Seiji Miyahara, Eiji Matsushima, Yayoi Takao, Takeshi Wakasa, Junko Taguchi, Kenichi Matsuo, Keisuke Yamamura, Khoon Tee Chong, Hitoshi Miyakoshi, Wakako Yano, Masayoshi Fukuoka, Kunihiro Yoshisue, Akio Fujioka
Publikováno v:
Molecular Cancer Therapeutics. 17:1683-1693
5-Fluorouracil (5-FU) is an antimetabolite and exerts antitumor activity via intracellularly and physiologically complicated metabolic pathways. In this study, we designed a novel small molecule inhibitor, TAS-114, which targets the intercellular met
Autor:
Hongyong Zhang, Susan D. Airhart, Bruce D. Hammock, Daniel Zhu, Jianlin Yuan, Fuli Wang, Chong-Xian Pan, Tzu-yin Lin, Weimin Yu, Ralph W deVere White, Paul T. Henderson, Maike Zimmermann, Jun Yang, Michael A. Malfatti, Kenneth W. Turteltaub, Ai Hong Ma, Sung Hee Hwang
Publikováno v:
Molecular Cancer Therapeutics. 17:474-483
Cisplatin-based therapy is highly toxic, but moderately effective in most cancers. Concurrent inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) results in antitumor activity and has organ-protective effects. The goal of this